At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,607 enrolled
Drug / intervention
300 IR +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating 300 IR and Placebo for Rhinitis, Allergic, Perennial and House Dust Mite Allergy. Completed, enrolled 1,607 participants across 2 sites in 2 countries.
Detailed Summary
The objective of this study was to assess the efficacy and safety of 12 months of treatment with 300 IR of STG320 sublingual tablets compared with placebo in adults and adolescents with HDM-associated allergic rhinitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartSep 2015
Primary CompletionJun 2018
TodayJul 2026
First PostedMay 14, 2015
Enrollment StartSep 29, 2015
Primary CompletionJun 25, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.1 years ago
Interventions
300 IRbiological
300 IR tablet of HDM Allergen Extracts
Placebobiological
Placebo tablet